Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H22F2N2O3S |
| Molecular Weight | 396.451 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)S(=O)(=O)NC[C@H](C)C1=CC=C(NC(=O)C2=CC(F)=CC(F)=C2)C=C1
InChI
InChIKey=ACOXQYLJOQAHST-ZDUSSCGKSA-N
InChI=1S/C19H22F2N2O3S/c1-12(2)27(25,26)22-11-13(3)14-4-6-18(7-5-14)23-19(24)15-8-16(20)10-17(21)9-15/h4-10,12-13,22H,11H2,1-3H3,(H,23,24)/t13-/m0/s1
| Molecular Formula | C19H22F2N2O3S |
| Molecular Weight | 396.451 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17504104
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17504104
LY-450108 had been in phase I clinical trial by Lilly, where was shown, that this drug safe and well tolerated in healthy subjects. This drug in the preclinical studies on animal models for the treatment of depression and Parkinson's disease.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17504104
Curator's Comment: # Eli Lilly & Co. Ltd
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2096670 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16554450 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| AMPA receptor potentiators: application for depression and Parkinson's disease. | 2007-05 |
|
| Multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects. | 2006-04 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16554450
open-label, multiple oral dose study evaluating 1 mg and 5 mg LY450108
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:06:11 GMT 2025
by
admin
on
Mon Mar 31 18:06:11 GMT 2025
|
| Record UNII |
JT47TQ8QOS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
376594-67-1
Created by
admin on Mon Mar 31 18:06:11 GMT 2025 , Edited by admin on Mon Mar 31 18:06:11 GMT 2025
|
PRIMARY | |||
|
DTXSID10431720
Created by
admin on Mon Mar 31 18:06:11 GMT 2025 , Edited by admin on Mon Mar 31 18:06:11 GMT 2025
|
PRIMARY | |||
|
9843690
Created by
admin on Mon Mar 31 18:06:11 GMT 2025 , Edited by admin on Mon Mar 31 18:06:11 GMT 2025
|
PRIMARY | |||
|
JT47TQ8QOS
Created by
admin on Mon Mar 31 18:06:11 GMT 2025 , Edited by admin on Mon Mar 31 18:06:11 GMT 2025
|
PRIMARY |